Home Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO
 

Keywords :   


Biotech Mailbag: Duchenne Drama, CAR-T Trouble, ASCO

2015-06-05 15:01:16| Biotech - Topix.net

It's weird, somewhat inappropriate and definitely risky for Biomarin given its DMD drug drisapersen is currently under FDA review. Sarepta Therapeutics If you're unsure what Steven is referring to, Biomarin and PTC Therapeutics are co-sponsoring an investor "symposium" on June 22 in New York City titled, Advances in Duchenne Muscular Dystrophy Natural History and Biomarkers .

Tags: cart trouble drama biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »